NO20016252L - Fremgangsmåte for nedregulering av GDF-8 aktivitet - Google Patents

Fremgangsmåte for nedregulering av GDF-8 aktivitet

Info

Publication number
NO20016252L
NO20016252L NO20016252A NO20016252A NO20016252L NO 20016252 L NO20016252 L NO 20016252L NO 20016252 A NO20016252 A NO 20016252A NO 20016252 A NO20016252 A NO 20016252A NO 20016252 L NO20016252 L NO 20016252L
Authority
NO
Norway
Prior art keywords
gdf
regulation
activity
procedure
Prior art date
Application number
NO20016252A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016252D0 (no
Inventor
Torben Halkier
Soeren Mouritsen
Steen Klysner
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of NO20016252D0 publication Critical patent/NO20016252D0/no
Publication of NO20016252L publication Critical patent/NO20016252L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Control Of Eletrric Generators (AREA)
NO20016252A 1999-07-20 2001-12-19 Fremgangsmåte for nedregulering av GDF-8 aktivitet NO20016252L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26
PCT/DK2000/000413 WO2001005820A2 (en) 1999-07-20 2000-07-20 Method for down-regulating gdf-8 activity

Publications (2)

Publication Number Publication Date
NO20016252D0 NO20016252D0 (no) 2001-12-19
NO20016252L true NO20016252L (no) 2002-03-15

Family

ID=26065065

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016252A NO20016252L (no) 1999-07-20 2001-12-19 Fremgangsmåte for nedregulering av GDF-8 aktivitet

Country Status (21)

Country Link
US (2) US7070784B1 (https=)
EP (1) EP1200119A2 (https=)
JP (1) JP2003506325A (https=)
KR (1) KR100750695B1 (https=)
CN (1) CN1384757A (https=)
AU (1) AU778470B2 (https=)
CA (1) CA2379852A1 (https=)
EA (1) EA005248B1 (https=)
EE (1) EE200200025A (https=)
HK (1) HK1048937A1 (https=)
HR (1) HRP20010900A2 (https=)
HU (1) HUP0201861A3 (https=)
IL (1) IL146845A0 (https=)
MX (1) MXPA01013232A (https=)
NO (1) NO20016252L (https=)
NZ (1) NZ517058A (https=)
PL (1) PL353855A1 (https=)
SK (1) SK722002A3 (https=)
TR (2) TR200400621T2 (https=)
WO (1) WO2001005820A2 (https=)
ZA (1) ZA200109901B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
JP4544742B2 (ja) * 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
BR0317538A (pt) * 2002-12-20 2005-11-29 Amgen Inc Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
EP1699820A2 (en) * 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
EP1799709B1 (en) 2004-09-30 2012-04-04 ORICO Limited Myostatin isoform
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
CN101522707B (zh) 2006-08-03 2013-08-28 莫约斯汀医疗有限公司 肌肉生长抑制素拮抗剂
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
CN103249835B (zh) * 2011-07-06 2015-05-20 湖北省农业科学院畜牧兽医研究所 猪肌抑素基因座位及其应用
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
KR20170135967A (ko) 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
MX2020008991A (es) 2018-03-01 2020-12-10 Regeneron Pharma Metodos para alterar la composicion corporal.
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US20240366760A1 (en) * 2023-01-17 2024-11-07 Regen BioPharma, Inc. Activation of survivin-specific immune responses using dendritic cell derived exosomes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
CN1178955C (zh) 1997-04-15 2004-12-08 法默卡有限公司 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗
AU756620B2 (en) * 1997-07-14 2003-01-16 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
CA2315256A1 (en) * 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
KR20020026544A (ko) 2002-04-10
TR200400621T2 (tr) 2004-08-23
ZA200109901B (en) 2003-05-28
KR100750695B1 (ko) 2007-08-22
TR200200133T2 (tr) 2002-05-21
WO2001005820A3 (en) 2001-07-19
EP1200119A2 (en) 2002-05-02
EE200200025A (et) 2003-04-15
MXPA01013232A (es) 2005-05-24
HK1048937A1 (zh) 2003-04-25
NO20016252D0 (no) 2001-12-19
IL146845A0 (en) 2002-07-25
EA200200182A1 (ru) 2002-06-27
NZ517058A (en) 2004-04-30
AU5967500A (en) 2001-02-05
WO2001005820A2 (en) 2001-01-25
CN1384757A (zh) 2002-12-11
PL353855A1 (en) 2003-12-01
HRP20010900A2 (en) 2003-08-31
HUP0201861A3 (en) 2004-07-28
US7056512B1 (en) 2006-06-06
US7070784B1 (en) 2006-07-04
JP2003506325A (ja) 2003-02-18
EA005248B1 (ru) 2004-12-30
CA2379852A1 (en) 2001-01-25
AU778470B2 (en) 2004-12-09
SK722002A3 (en) 2003-02-04
HUP0201861A2 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
NO20016252L (no) Fremgangsmåte for nedregulering av GDF-8 aktivitet
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
DE60028307D1 (de) Eliminierung von interferenzsignalen
NO20014535D0 (no) Inhibitorer av IMPDH-enzym
NO20010844D0 (no) Regulering av substrataktivitet
NO20021474L (no) Forbindelser for behandling av ischemi
HUP0002224A3 (en) Benzimidazole derivatives of antivirus activity
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20020365L (no) Oligonukleotider for inhibiering av ekspresjonen av humant eg5
NO20013507L (no) Blandinger for behandling av inflammatoriske reaksjoner
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
DE60010553D1 (de) Interferenzunterdrückungsverfahren
ID24677A (id) Kombinasi senyawa aktif fungisidal
NO20006279D0 (no) Generator for produksjon av fotonantalltilstand
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
PT1175417E (pt) Compostos substituidos de benzolactamas
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20014026D0 (no) Krampestillende derivater til behandling av betydelig skjelving
FR2790597B1 (fr) Integration de condensateurs
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
NO993313L (no) Derivater av 5-nitrofurfural
SE9902239D0 (sv) Kornisch bestående av flera delar

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application